References
- Watanabe T, Yuki S, Egawa M, Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 1994;268:1597–604.
- Yamamoto T, Yuki S, Watanabe T, Mitsuka M, Saito K, Kogure K. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res. 1997;762:240–2.
- Mizuno A, Umemura K, Nakashima M. Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following the rat middle cerebral artery occlusion. Gen Pharmacol. 1998;30:575–8.
- Edaravone Acute Brain Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15:222–9.
- Ikeda K, Iwasaki Y, Kinoshita M. Treatment of wobbler mice with free radical scavenger. In: Molecular mechanism and therapeutics of amyotrophic lateral sclerosis. Amsterdam: Elsevier Science; 2001:335–340.
- Watanabe T, Morita I, Nishi H, Murota S. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids. 1988;33:81–7.
- Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–17.
- The Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Suppl). [Epub ahead of print]. doi: 10.1080/21678421.2017.1363780.
- The Writing Group on behalf of the Edaravone (MCI-186) ALS 17 Study Group. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Suppl). [Epub ahead of print]. doi: 10.1080/21678421.2017.1362000.
- The Writing Group on behalf of the Edaravone (MCI-186) ALS 18 Study Group. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS Severity Classification: Grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(Suppl). [Epub ahead of print]. doi: 10.1080/21678421.2017.1361441.
- The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
- Brooks BR, Miller RG, Swash M, Munsat T; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
- Norris FH,Jr., Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 1974;24:721–8.
- Oda E, Ohashi Y, Tashiro K, Mizuno Y, Kowa H, Yanagisawa N. Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis. No To Shinkei. 1996;48:999–1007. [article in Japanese].
- Jenkinson C, Fitzpatrick R, Brennen C, Swash M. Evidence for the validity and reliability of the ALS assessment questionnaire: the ALSAQ40. Amyotroph Lateral Scler Other Motor Neuron Disord. 1999;1:33–40.
- Yamaguchi T, Ohbu S, Saito M, Ito Y, Moriwaka F, Tashikiro K, et al. Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis: assessment questionnaire 40 (ALSAQ-40). No To Shinkei. 2004;56:483–94. [article in Japanese].